Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Garnick

Showing results (181-190 of 305) with videos related to

Pageof 31
Sort By:
Inquiry : a Journal of Medical Care Organization, Provision and Financing|January 1, 1986
The role of specialized clinical services in competition among hospitalsH S Luft, J C Robinson, D W Garnick, et al.
Urology|October 1, 1996
Leydig cell hyperplasia mimicking testicular neoplasmA F Olumi, M B Garnick, A A Renshaw, et al.
Clinical Pharmacology and Therapeutics|April 24, 2003
Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancerShekman L Wong, David T-W Lau, Sharon A Baughman, et al.
Urology|November 17, 2001
A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancerD McLeod, N Zinner, K Tomera, et al.
Medical Care|November 1, 1988
Hospital volume and patient outcomes. The case of hip fracture patientsR G Hughes, D W Garnick, H S Luft, et al.
Radiology|September 1, 1991
CT and pathologic predictive features of residual mass histologic findings after chemotherapy for nonseminomatous germ cell tumors: can residual malignancy or teratoma be excluded?P C Stomper, L A Kalish, M B Garnick, et al.
Blood|February 15, 1990
In vivo hematologic effects of recombinant human macrophage colony-stimulating factorT R Ulich, J del Castillo, L R Watson, et al.
BJU International|July 6, 2013
The utility of prostate-specific antigen in the management of advanced prostate cancerE David Crawford, Charles L Bennett, Gerald L Andriole, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1988
Stage I nonseminomatous germ cell testicular tumor: prediction of metastatic potential by primary histopathologyC Y Fung, L A Kalish, G L Brodsky, et al.
Journal of Substance Abuse Treatment|June 26, 2009
The Washington Circle continuity of care performance measure: predictive validity with adolescents discharged from residential treatmentBryan R Garner, Mark D Godley, Rodney R Funk, et al.
Pageof 31

Showing results (181-190 of 305) with videos related to

Sort By:
Pageof 31
Inquiry : a Journal of Medical Care Organization, Provision and Financing|January 1, 1986
The role of specialized clinical services in competition among hospitalsH S Luft, J C Robinson, D W Garnick, et al.
Urology|October 1, 1996
Leydig cell hyperplasia mimicking testicular neoplasmA F Olumi, M B Garnick, A A Renshaw, et al.
Clinical Pharmacology and Therapeutics|April 24, 2003
Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancerShekman L Wong, David T-W Lau, Sharon A Baughman, et al.
Urology|November 17, 2001
A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancerD McLeod, N Zinner, K Tomera, et al.
Medical Care|November 1, 1988
Hospital volume and patient outcomes. The case of hip fracture patientsR G Hughes, D W Garnick, H S Luft, et al.
Radiology|September 1, 1991
CT and pathologic predictive features of residual mass histologic findings after chemotherapy for nonseminomatous germ cell tumors: can residual malignancy or teratoma be excluded?P C Stomper, L A Kalish, M B Garnick, et al.
Blood|February 15, 1990
In vivo hematologic effects of recombinant human macrophage colony-stimulating factorT R Ulich, J del Castillo, L R Watson, et al.
BJU International|July 6, 2013
The utility of prostate-specific antigen in the management of advanced prostate cancerE David Crawford, Charles L Bennett, Gerald L Andriole, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1988
Stage I nonseminomatous germ cell testicular tumor: prediction of metastatic potential by primary histopathologyC Y Fung, L A Kalish, G L Brodsky, et al.
Journal of Substance Abuse Treatment|June 26, 2009
The Washington Circle continuity of care performance measure: predictive validity with adolescents discharged from residential treatmentBryan R Garner, Mark D Godley, Rodney R Funk, et al.
Pageof 31